Standard vs Abbreviated Regulatory Pathways for Medical Devices in Mexico

1. Key takeaways

Mexico operates two registration pathways. The standard pathway requires a complete technical dossier and subjects the application to both an administrative and a technical review by COFEPRIS. The abbreviated regulatory pathway (Vía Regulatoria Abreviada), established under the guidelines published in DOF 2025-07-18, allows COFEPRIS to rely on evaluations already performed by reference regulatory authorities: the applicant submits a summary dossier, and the decision on the device is issued within 30 business days. Which pathway applies is not a matter of preference. It depends on two questions: whether the product already holds a qualifying approval from a reference authority, and whether the version submitted in Mexico is fully identical to the version that was approved. If either condition fails, the abbreviated route is unavailable and the standard route becomes the only option. In practice this means the pathway decision is made before drafting begins: it rests on evidence that already exists in the reference country, namely the approval itself together with its issuing authority, its procedure type and its date, and not on anything the applicant can construct afterwards. Understanding this branching logic before the dossier is written saves both the filing fee and the review time that a mis-routed application would consume.

2. Legal basis

The two pathways rest on different legal instruments: the abbreviated route on the 2025 guidelines and the low-risk agreement, the standard route on the implementing regulation. The homoclave agreement ties the two frameworks together by assigning the application codes. Because each instrument governs a different aspect of the filing, every element of the chosen pathway should be traceable to one of these sources before the dossier is submitted. The table below sets out each instrument, its date or articles, and the operational point it establishes.

3. Expert insights

Insight 1: the legal basis of the abbreviated pathway is reliance, not mutual recognition. The guidelines state plainly that COFEPRIS takes into account evaluations already completed by reference regulatory authorities; they do not recognize that a foreign approval automatically has effect in Mexico. The product must still obtain its own Mexican registro sanitario. Teams that describe the route as mutual recognition tend to underestimate the work involved: the Mexican application, the Mexican holder, the Mexican labeling and the Mexican certificate all remain necessary, only the depth of the technical evidence changes.

Insight 2: the abbreviated pathway has three hard prerequisites. First, the product must come from a regulatory decision of a country that is a member of the IMDRF Management Committee, or from a member of the MDSAP framework. Second, the reference approval must have been obtained through a conventional procedure; emergency use authorizations, accelerated approvals and conditional approvals are all excluded. Third, the reference approval must have been obtained no more than 5 years before the application. All three conditions must hold simultaneously, and a failure of any single one disqualifies the route.

Insight 3: the documentation depth differs, but the number of obligations does not. Under the abbreviated pathway the applicant may dispense with the full clinical report, the raw biocompatibility data and the detailed design documentation, submitting a summary instead. But the obligations attached to the certificate are not reduced: the holder arrangements, labeling, technovigilance and import authorization obligations all remain in force exactly as they do for the standard pathway. A lighter dossier never means a lighter compliance footprint. In other words, the abbreviated route shortens the review, not the responsibility, and the post-registration obligations must be budgeted exactly as they would be for a standard pathway certificate.

Insight 4: 2025 also created a faster low-risk channel. Low-risk devices listed in Annex I of the agreement carry a commitment of a decision within 20 business days, which is faster than the 30 business days of the abbreviated pathway. The channel, however, applies only to the 93 items enumerated in the list, and eligibility follows the listing, not the manufacturer’s own assessment of risk. For products on that list it should be the first option examined; for everything else it is simply unavailable.

Insight 5: the old equivalence pathway was closed in October 2025. Under the agreement published in DOF 2025-08-22, from 2025-10-06 onward applications based on the former equivalence arrangements with the FDA, Health Canada and other authorities are no longer accepted. All applications now proceed under the new homoclave codes and, where eligible, the new abbreviated pathway. Legacy templates prepared before the switch must not be reused, and any checklist still referencing the old codes should be retired at the same time.

4. Practical recommendations

• Begin with a reference approval usability assessment covering four checks: the reference country, the type of approval, the date it was obtained, and the identity of the product. Only when all four pass should the abbreviated pathway be selected.
• If the product differs in any material, design or process respect from the reference version, prepare directly under the standard pathway instead of gambling on the breadth of the review.
• Even under the abbreviated pathway, prepare the summary dossier properly: description, manufacturing process, conformity assessment, packaging, risk analysis and the post-market plan must all be included.
• For low-risk products, check Annex I first; if the 20 business day channel applies, schedule that route with priority.
• After October 2025, do not submit under the old equivalence pathway under any circumstances.

5. Verification checklist

• □ Confirmed that the reference regulatory authority is within the reliance list
• □ Confirmed that the reference approval was obtained through a conventional procedure
• □ Confirmed that the reference approval was obtained within the last 5 years
• □ Confirmed that the product is fully identical to the reference version
• □ The elements of the summary dossier are complete
• □ Confirmed that the old equivalence pathway closed on 2025-10-06 is not being relied upon

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com